---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133770"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:02:55.231656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024

## Summary
- Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.
- Net loss of $48.5M for Q1 2024, compared to $68.2M in Q1 2023.
- THRIVE global phase 3 trial in active TED enrolled 113 patients (exceeded target of 90); topline data expected September 2024.
- Positive FDA Type C meeting for VRDN-003 subcutaneous candidate; pivotal program on track to start mid-2024.
- VRDN-006 FcRn inhibitor IND submission on track for year-end 2024; VRDN-008 NHP data expected H2 2024.

## SEC filing metadata
- accession: 0001193125-24-133770
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/d823086d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133770
- JSON: https://secwatch.observer/filing/0001193125-24-133770.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133770.txt

## Key facts
- Earnings Releases
  Viridian Therapeutics, Inc.\DE reported first quarter ended March 31, 2024 results: net income $48.5 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $48.5 million
  - Result: reported results
  source text: The company’s net loss was $48.5 million for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.